Laszlo Feher, DO
Geriatric Medicine · New York, NYNPI 1205932290
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 176 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$717
- Pfizer$345
- Lilly USA, LLC$323
- E.r. Squibb & Sons, L.L.C.$314
- GSK$290
- Amarin Pharma, Inc.$286
- plus $2K from 20 others
What the payments were for
- Food & beverage$3,96499%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $717 |
| Pfizer | 17 | $345 |
| Lilly USA, LLC | 14 | $323 |
| E.r. Squibb & Sons, L.L.C. | 14 | $314 |
| GSK | 13 | $290 |
| Amarin Pharma, Inc. | 5 | $286 |
| AstraZeneca(2 entities) | 13 | $238 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $235 |
| Astellas Pharma US Inc | 10 | $233 |
| AbbVie(2 entities) | 10 | $184 |
| Boehringer Ingelheim | 6 | $171 |
| Bausch Health US, LLC | 7 | $168 |
| Johnson & Johnson | 5 | $123 |
| Amgen | 3 | $60 |
| Merck | 2 | $55 |
| Novartis | 2 | $46 |
| Mylan Specialty L.p. | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Shield Therapeutics Inc | 1 | $28 |
| Philips North America LLC | 2 | $27 |
| Bayer | 1 | $19 |
| Mannkind Corporation | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,019 in reported general payments places this provider in the 90th percentile of 400 geriatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $117,639 |
| EliquisApixaban | 94 | $102,490 |
| XifaxanRifaximin | 14 | $65,539 |
| JardianceEmpagliflozin | 44 | $59,391 |
| MounjaroTirzepatide | 35 | $41,840 |
| RybelsusSemaglutide | 15 | $40,007 |
| MyrbetriqMirabegron | 43 | $36,804 |
| JanuviaSitagliptin Phosphate | 18 | $28,714 |
| XareltoRivaroxaban | 25 | $27,289 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $21,442 |
| TrulicityDulaglutide | 11 | $19,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,102 |
| SynthroidLevothyroxine Sodium | 97 | $8,852 |
| Dexlansoprazole DrDexlansoprazole | 13 | $6,497 |
| Levothyroxine Sodium | 286 | $6,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $717 | $157,645101 claims |
| PfizerEliquis, Paxlovid | $345 | $106,716129 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $235 | $65,53914 claims |
| Lilly USA, LLCMounjaro, Trulicity | $323 | $61,40346 claims |
| Boehringer IngelheimJardiance | $171 | $59,39144 claims |
| Astellas Pharma US IncMyrbetriq | $233 | $36,80443 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $290 | $34,54470 claims |
| MerckJanuvia | $55 | $28,71418 claims |
| Johnson & JohnsonXarelto | $123 | $27,28925 claims |
| AbbVieSynthroid | $184 | $8,85297 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $17 | $2,86011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 geriatric medicine providers in New York.
Other geriatric medicine in New York
- Howard FillitNew York$42K
- Alexandra FingestenNew York$9K
- Lisa BabitzNew York$6K
- Eric ManheimerNew York$3K
- Sharda RamsaroopNew York$2K
- Sofya KleynNew York$2K
- Eileen CallahanNew York$2K
- Wen DombrowskiBrooklyn$45K
- Sharon BrangmanSyracuse$45K
- Adam CohenGreat Neck$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.